November 24, 2016
Kenshi Suzuki, director of the Japan Red Cross Medical Center’s Myeloma and Amyloidosis Center, praised the efficacy of a combination therapy using Empliciti (elotuzumab), the first antibody drug for the treatment of multiple myeloma, and Revlimid (lenalidomide). At a media...read more